Health / Biotech

MBX Biosciences Canvuparatide Shows Promise in Hypoparathyroidism Treatment

MBX Biosciences (Nasdaq: MBX) has announced positive results from its Phase 2 Avail™ trial for canvuparatide, a once-weekly drug for treating chronic hypoparathyroidism (HP). The trial demonstrated a 63% responder rate at 12 weeks and a 79%...